Skip to main content

Table 3 Comparisons of demographic and clinical parameters according to metabolic health and insulin resistance status

From: The impact of insulin resistance on the association between metabolic syndrome and lung function: the Kangbuk Samsung Health Study

 

All Subjects

(n = 114,143)

MH

(n = 56,311)

(49.3%)

MS without IR

(n = 40,255)

(35.3%)

MS with IR

(n = 17,577)

(15.4%)

p value

Age (≥ 40 years)

49,240 (43.1)

19,212 (34.1)

22,398 (55.6)

7,630 (43.4)

< 0.001

Sex (male)

65,342 (57.2)

23,430 (41.6)

29,751 (73.9)

12,161 (69.2)

< 0.001

Center (Seoul)

56,201 (49.2)

29,434 (52.3)

20,179 (50.1)

6,588 (37.5)

< 0.001

Obesity: BMI (≥ 25 kg/m2)

34,877 (30.6)

8,184 (14.5)

14,721 (36.6)

11,972 (68.1)

< 0.001

Current smokers

18,991 (16.6)

6,166 (10.9)

9,096 (22.6)

3,729 (21.2)

< 0.001

Heavy alcohol intake (> 20 g/day)

22,746 (19.9)

7,716 (13.7)

10,796 (26.8)

4,237 (24.1)

< 0.001

Regular exercise (≥ 3 times/week) (n = 113,742)

15,346 (13.5)

7,743 (13.8)

5,863 (14.6)

1,740 (9.9)

< 0.001

High education (≥ college education) (n = 111,747)

94,181 (84.3)

47,630 (86.2)

32,687 (83.1)

13,864 (80.7)

< 0.001

Elevated bilirubin (> 1.9 mg/dL)

1,564 (1.4)

799 (1.4)

622 (1.5)

143 (0.8)

< 0.001

Elevated ALT (> 40 U/L) (n = 113,969)

11,270 (9.9)

1,982 (3.5)

4,358 (10.8)

4,930 (28.1)

< 0.001

Elevated serum creatinine (> 1.2 mg/dL)

454 (0.4)

91 (0.2)

253 (0.6)

110 (0.6)

< 0.001

Hypercholesterolemia (≥ 220 mg/dL)

23,491 (20.6)

6,836 (12.1)

11,584 (28.8)

5,071 (28.9)

< 0.001

Hypertriglyceridemia (≥ 150 mg/dL)

25,290 (22.2)

0 (0.0)

16,177 (40.2)

9,113 (51.8)

< 0.001

Low HDL cholesterola

12,759 (11.2)

0 (0.0)

8,093 (20.1)

4,666 (26.5)

< 0.001

High LDL cholesterol (≥ 159 mg/dL)

17,001 (14.9)

4,099 (7.3)

9,003 (22.4)

3,899 (22.2)

< 0.001

Hyperglycemia at fasting (≥ 100 mg/dl)

22,287 (19.5)

0 (0.0)

13,524 (33.6)

8,763 (49.9)

< 0.001

High HbA1c > = 6.5

2,144 (1.9)

2 (0.0)

827 (2.1)

1,315 (7.5)

< 0.001

Elevated hsCRP (> 0.5 mg/l) (n = 88,275)

2,246 (2.5)

795 (1.8)

811 (2.6)

640 (4.6)

< 0.001

High HOMA-IR ≥ 2.5

17,404 (15.2)

0 (0.0)

0 (0.0)

17,404 (99.0)

< 0.001

High insulin ≥ 25

623 (0.5)

0 (0.0)

0 (0.0)

623 (3.5)

< 0.001

High SBP ≥ 130

7,438 (6.5)

0 (0.0)

4,813 (12.0)

2,625 (14.9)

< 0.001

FVC% <80%

4,247 (3.7)

1,681 (3.0)

1,621 (4.0)

945 (5.4)

< 0.001

FEV1% <80%

4,878 (4.3)

1,925 (3.4)

1,924 (4.8)

1,029 (5.9)

< 0.001

FEV1(L)/FVC(L) ratio < 0.7

2,121 (1.9)

774 (1.4)

1,030 (2.6)

317 (1.8)

< 0.001

  1. Data are presented as mean ± standard deviation, median and (interquartile range), or number of subjects with percentage in parentheses. We recorded subject numbers with available clinical parameters. Unless otherwise indicated, the available subject number was 114,143
  2. aLow HDL was defined as < 40 mg/dL in males and < 50 mg/d/L in females
  3. ALT = alanine aminotransferase; BMI = body mass index; BP = blood pressure; FEV1% = percent predicted forced expiratory volume in 1 s; FVC% = percent predicted forced vital capacity; HDL = high-density lipoprotein; HbA1c = hemoglobin A1c; HOMA-IR = homeostasis model assessment of insulin resistance; hs-CRP = high-sensitivity C-reactive protein; IR = insulin resistance; LDL = low-density lipoprotein; MH = metabolically healthy; MS = metabolic syndrome
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us